Petter Bjornstad1,2, Robert H Eckel3. 1. Department of Pediatrics, Division of Endocrinology, University of Colorado School of Medicine, 13123 East 16th Ave, Box B26, Aurora, CO, 80045, USA. petter.bjornstad@childrenscolorado.org. 2. Department of Medicine, Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO, USA. petter.bjornstad@childrenscolorado.org. 3. Department of Medicine, Division of Endocrinology and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA. Robert.Eckel@ucdenver.edu.
Abstract
PURPOSE OF REVIEW: Insulin resistance (IR) is recognized to play an important role in the pathogenesis of dyslipidemia. This review summarizes the complex interplay between IR and dyslipidemia in people with and without diabetes. RECENT FINDINGS: IR impacts the metabolism of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C) by several mechanisms. Trials with insulin sensitizing therapies, including biguanides and thiazolidinediones, have provided inconsistent results on lipid lowering in people with and without diabetes. In this review, we focus on the pathophysiological interplay between IR and dyslipidemia and recapitulate lipid and lipoprotein data from insulin-sensitizing trials. Further research elucidating the reciprocal relationship between IR and dyslipidemia is needed to better target these important risk factors for cardiovascular disease.
PURPOSE OF REVIEW: Insulin resistance (IR) is recognized to play an important role in the pathogenesis of dyslipidemia. This review summarizes the complex interplay between IR and dyslipidemia in people with and without diabetes. RECENT FINDINGS: IR impacts the metabolism of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C) by several mechanisms. Trials with insulin sensitizing therapies, including biguanides and thiazolidinediones, have provided inconsistent results on lipid lowering in people with and without diabetes. In this review, we focus on the pathophysiological interplay between IR and dyslipidemia and recapitulate lipid and lipoprotein data from insulin-sensitizing trials. Further research elucidating the reciprocal relationship between IR and dyslipidemia is needed to better target these important risk factors for cardiovascular disease.
Authors: Melanie Cree-Green; David M Maahs; Annie Ferland; John E Hokanson; Hong Wang; Laura Pyle; Gregory L Kinney; Martina King; Robert H Eckel; Kristen J Nadeau Journal: Pediatr Diabetes Date: 2015-06-17 Impact factor: 4.866
Authors: Alina C R Feitosa; Gilson S Feitosa-Filho; Fatima R Freitas; Bernardo L Wajchenberg; Raul C Maranhão Journal: Lipids Health Dis Date: 2013-02-11 Impact factor: 3.876
Authors: José G González-González; Jorge R Violante-Cumpa; Miguel Zambrano-Lucio; Erick Burciaga-Jimenez; Patricia L Castillo-Morales; Mariano Garcia-Campa; Ricardo César Solis; Alejandro D González-Colmenero; René Rodríguez-Gutiérrez Journal: High Blood Press Cardiovasc Prev Date: 2022-10-01
Authors: Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow Journal: J Clin Lipidol Date: 2020-11-24 Impact factor: 4.766